Search
Harbour BioMed has released preclinical research data for LET003, its first monoclonal antibody drug targeting ACVR2A/2B developed using the Hu-mAtrIx™ AI platform. The data shows that LET003 exhibits superior pharmacokinetic characteristics compared to multiple competitors and enhances fat loss while preserving lean body mass when used in combination with semaglutide. At low doses, its ability to promote lean body mass increase is comparable to that of high-dose bimagrumab, demonstrating potential as a best-in-class therapy for obesity treatment. Founder Dr. Wang Jinsong stated that the advancement of LET003 is attributed to the Hu-mAtrIx™ platform. He is excited about the drug's preclinical performance and looks forward to advancing it into clinical trials as soon as possible to provide a new treatment option for obesity patients.
-
C114 Communication Network -
Communication Home
